On Wednesday, The Right Place and the City of Grand Rapids announced the approval of an incentive that will bring 37 new high-tech, life science jobs and $2.8 million in new investment to Grand Rapids over the next three years.

Grand Rapids-based NxGen MDx plans to expand at its current location, 801 Broadway Ave NW Suite 203, Grand Rapids, MI 49504. The new expansion will increase the laboratory’s testing capacity.

NxGen MDx offers genetic screening for inherited diseases such as Cystic Fibrosis, Spinal Muscular Atrophy, and Fragile X Syndrome.

“We chose to launch NxGen in Grand Rapids back in 2014 within its prestigious medical corridor to offer our patients the very best and brightest of the genetics field,” said Kristin Sherman, Chief Financial Officer, NxGen MDx.

“Grand Rapids’ life sciences cluster continues to see significant growth, and NxGen is yet the latest example of that growth,” said Eric Icard, Senior Business Development Manager, The Right Place, Inc. and project lead on the expansion.

West Michigan was chosen over a competing location in Florida.

The City of Grand Rapids is considering the approval of a local Property Tax Abatement to provide support for NxGen’s capital investment.